Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ004309 + atezolizumab in advanced solid tumors
NCT05001347Phase 2Completed
- Sponsor
- I-Mab
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of uliledlimab in ovarian cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by I-Mab. Primary endpoint: Objective Response Rate at 66 weeks. Started Nov 2021; status: completed.
02
Drugs
uliledlimab
03
Conditions
ovarian cancerhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)gastrointestinal cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05001347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001347.